Quick Answer
Spero Therapeutics, Inc. reported Net Income Loss of -$41.66 million for the year ending 2018.
- Spero Therapeutics, Inc. showed a decrease of -7.5% in Net Income Loss from 2017 to 2018.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 14, 2019.
- XBRL data for this metric is available from 2015 to 2018 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$5.91 million | Q2 2016: -$6.06 million | Q3 2016: -$6.32 million | Q4 2016: -$7.21 million | Q1 2017: -$5.88 million | Q2 2017: -$9.17 million | Q3 2017: -$9.84 million | Q4 2017: -$13.86 million | Q1 2018: -$10.64 million | Q2 2018: -$9.96 million | Q3 2018: -$10.46 million.
- Over the full 4 years of available data (2015 to 2018), Spero Therapeutics, Inc.'s Net Income Loss has declined by 310.3%.
- Historical annual values: Fiscal year 2018: -$41.66 million | Fiscal year 2017: -$38.74 million | Fiscal year 2016: -$25.49 million | Fiscal year 2015: -$10.15 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: